Renaissance Technologies
THRX

Renaissance Technologies’s Theseus Pharmaceuticals, Inc. Common Stock THRX Stock Holding History

Renaissance Technologies’s Portfolio THRX Stock Details THRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-271,600
Closed -$1.1M – 4217
2023
Q4 		$1.1M Buy
271,600
+145,406
+115% +$444K ﹤0.01% 2346
2023
Q3 		$339K Buy
126,194
+84,994
+206% +$333K ﹤0.01% 2876
2023
Q2 		$384K Sell
41,200
-89,400
-68% -$881K ﹤0.01% 3009
2023
Q1 		$1.16M Buy
130,600
+111,800
+595% +$1.1M ﹤0.01% 2381
2022
Q4 		$94K Buy
+18,800
New +$110K ﹤0.01% 3643

Renaissance Technologies's THRX Position: Q1 2024 in Review

Renaissance Technologies sold out of Theseus Pharmaceuticals, Inc. Common Stock (THRX) in Q1 2024, closing a stake of 271,600 shares — an estimated $1.1M sold.

Renaissance Technologies first reported a position in THRX in Q4 2022 and held it in 5 quarters. The position peaked at $1.16M in Q1 2023. 1 fund tracked by Wall St. Rank holds THRX as of Q1 2024.

  • Renaissance Technologies reported no remaining Theseus Pharmaceuticals, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Renaissance Technologies sold 271,600 Theseus Pharmaceuticals, Inc. Common Stock shares in Q1 2024, an estimated $1.1M.
  • Renaissance Technologies first reported a position in Theseus Pharmaceuticals, Inc. Common Stock in Q4 2022 and held it in 5 quarters.
  • Renaissance Technologies's Theseus Pharmaceuticals, Inc. Common Stock position peaked at $1.16M in Q1 2023.
  • 1 fund tracked by Wall St. Rank held Theseus Pharmaceuticals, Inc. Common Stock as of Q1 2024.

Based on Renaissance Technologies's 13F filing for Q1 2024, filed 13 May 2024.